Barinthus Biotherapeutics plc (BRNS) - Total Assets
Based on the latest financial reports, Barinthus Biotherapeutics plc (BRNS) holds total assets worth $109.20 Million USD as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Barinthus Biotherapeutics plc - Total Assets Trend (2019–2024)
This chart illustrates how Barinthus Biotherapeutics plc's total assets have evolved over time, based on quarterly financial data. Also see Barinthus Biotherapeutics plc stock valuation for the company's overall valuation and market capitalisation.
Barinthus Biotherapeutics plc - Asset Composition Analysis
Current Asset Composition (December 2024)
Barinthus Biotherapeutics plc's total assets of $109.20 Million consist of 78.4% current assets and 21.6% non-current assets. Review Barinthus Biotherapeutics plc debt and liabilities to assess the company's total debt and financial obligations.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 69.0% |
| Accounts Receivable | $13.00 Million | 8.1% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $21.95 Million | 13.7% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2019–2024)
This chart illustrates how Barinthus Biotherapeutics plc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. See BRNS stock price and chart for real-time trading data and today's change.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Barinthus Biotherapeutics plc's current assets represent 78.4% of total assets in 2024, a decrease from 85.3% in 2019.
- Cash Position: Cash and equivalents constituted 69.0% of total assets in 2024, up from 60.0% in 2019.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 13.0% of total assets, an increase from 0.0% in 2019.
- Asset Diversification: The largest asset category is intangible assets at 13.7% of total assets.
Barinthus Biotherapeutics plc Competitors by Total Assets
Key competitors of Barinthus Biotherapeutics plc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
ALK-Abelló A/S
CO:ALK-B
|
Denmark | Dkr9.17 Billion |
|
Mirum Pharmaceuticals Inc
NASDAQ:MIRM
|
USA | $890.92 Million |
|
Xiamen Amoytop Biotech Co Ltd
SHG:688278
|
China | CN¥3.21 Billion |
|
BB Biotech AG
SW:BION
|
Switzerland | CHF3.09 Billion |
|
Soleno Therapeutics Inc
NASDAQ:SLNO
|
USA | $608.39 Million |
|
Nanobiotix
NASDAQ:NBTX
|
USA | $67.76 Million |
|
Inhibrx Biosciences, Inc.
NASDAQ:INBX
|
USA | $183.97 Million |
|
Wuhan Keqian Biology Co Ltd
SHG:688526
|
China | CN¥4.75 Billion |
Barinthus Biotherapeutics plc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 8.04 | 8.93 | 6.27 |
| Quick Ratio | 8.04 | 8.93 | 6.27 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $75.98 Million | $119.58 Million | $40.26 Million |
Barinthus Biotherapeutics plc - Advanced Valuation Insights
This section examines the relationship between Barinthus Biotherapeutics plc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 0.34 |
| Latest Market Cap to Assets Ratio | 0.18 |
| Asset Growth Rate (YoY) | -25.3% |
| Total Assets | $160.33 Million |
| Market Capitalization | $28.99 Million USD |
Valuation Analysis
Below Book Valuation: The market values Barinthus Biotherapeutics plc's assets below their book value (0.18x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Barinthus Biotherapeutics plc's assets decreased by 25.3% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Barinthus Biotherapeutics plc (2019–2024)
The table below shows the annual total assets of Barinthus Biotherapeutics plc from 2019 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $160.33 Million | -25.26% |
| 2023-12-31 | $214.51 Million | -20.61% |
| 2022-12-31 | $270.20 Million | -3.74% |
| 2021-12-31 | $280.71 Million | +454.05% |
| 2020-12-31 | $50.67 Million | +166.06% |
| 2019-12-31 | $19.04 Million | -- |
About Barinthus Biotherapeutics plc
Barinthus Biotherapeutics plc, a clinical-stage biopharmaceutical company, focuses on developing immunotherapeutic drug candidates for treating auto-immune and inflammatory diseases. Its lead candidate is VTP-1000, which is in Phase 1 clinical trial to restore immune non-responsiveness to gluten in patients with celiac disease. The company is also developing VTP-300, an immunotherapeutic targetin… Read more